Patents by Inventor Brit MOLLENHAUER

Brit MOLLENHAUER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10100367
    Abstract: The use of specific microRNAs (miRNAs) present in CSF as biomarkers for particular brain malignancies and disease activity.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: October 16, 2018
    Assignees: The Regents of the University of California, The Brigham and Women's Hospital, Inc.
    Inventors: Anna M. Krichevsky, Nadiya Teplyuk, Santosh Kesari, Brit Mollenhauer
  • Publication number: 20170342505
    Abstract: The use of specific microRNAs (miRNAs) present in CSF as biomarkers for particular brain malignancies and disease activity.
    Type: Application
    Filed: June 13, 2017
    Publication date: November 30, 2017
    Inventors: Anna M. Krichevsky, Nadiya Teplyuk, Santosh Kesari, Brit Mollenhauer
  • Publication number: 20160115549
    Abstract: The use of specific microRNAs (miRNAs) present in CSF as biomarkers for particular brain malignancies and disease activity.
    Type: Application
    Filed: October 5, 2015
    Publication date: April 28, 2016
    Inventors: Anna M. Krichevsky, Nadiya Teplyuk, Santosh Kesari, Brit Mollenhauer
  • Patent number: 9150928
    Abstract: The use of specific microRNAs (miRNAs) present in CSF as biomarkers for particular brain malignancies and disease activity.
    Type: Grant
    Filed: November 16, 2011
    Date of Patent: October 6, 2015
    Assignees: The Brigham and Women's Hospital, Inc., The Regents of the University of California
    Inventors: Anna M. Krichevsky, Nadiya Teplyuk, Brit Mollenhauer, Santosh Kesari
  • Publication number: 20130344063
    Abstract: The use of specific microRNAs (miRNAs) present in CSF as biomarkers for particular brain malignancies and disease activity.
    Type: Application
    Filed: November 16, 2011
    Publication date: December 26, 2013
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Anna M. Krichevsky, Nadiya Teplyuk, Brit Mollenhauer, Santosh Kesari
  • Publication number: 20110159527
    Abstract: Methods and diagnostic kits for determining whether a subject may develop a or for diagnosing a neurodegenerative disease. The method includes quantitating the amount of alpha-synuclein and total protein in a cerebrospinal fluid (CSF) sample obtained from the subject and calculating a ratio of alpha-synuclein to total protein content; comparing the ratio of alpha-synuclein to total protein content in the CSF sample with the alpha-synuclein to total protein content ratio in CSF samples obtained from healthy neurodegenerative disease-free subjects; and (c) determining from the comparison whether the subject has a likelihood to develop neurodegenerative disease or making a diagnosis of neurodegenerative disease in a subject. A difference in the ratio of alpha-synuclein to total protein content indicates that the subject has a likelihood to develop a neurodegenerative disease or has developed a neurodegenerative disease.
    Type: Application
    Filed: June 15, 2009
    Publication date: June 30, 2011
    Inventors: Michael Gebhard Schlossmacher, Brit Mollenhauer, Omar M.A. El Agnaf
  • Publication number: 20100167948
    Abstract: The present invention is directed to assay methods in which the levels of certain specific microRNAs are determined in the cerebrospinal fluid of a subject. These methods may be used in the diagnosis or monitoring of neurological diseases, especially brain tumors.
    Type: Application
    Filed: May 21, 2008
    Publication date: July 1, 2010
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Anna Krichevsky, Brit Mollenhauer
  • Publication number: 20090239311
    Abstract: In an ex vivo method of differentially diagnosing dementias selected from a group of demetias, which includes vascular dementias and frontotemporal lobe degenerations, a concentration of at least one carboxy-terminally truncated amyloid ? peptide species as a biomarker is determined in a body fluid obtained from a patient, the at least one carboxy-terminally truncated amyloid ? peptide species being selected from the group of species consisting of A?1-38, A?1-37 and A?1-39; and the concentration of the at least one carboxy-terminally truncated amyloid ? peptide species is compared to a threshold concentration value for the respective one carboxy-terminally truncated amyloid ? peptide species.
    Type: Application
    Filed: May 15, 2009
    Publication date: September 24, 2009
    Applicants: Friedrich-Alexander-Universitat Erlangen-Nurnberg, Georg-August-Universitat Gottingen Stiftung Offentlichen Rechts (Universitatsmedizin)
    Inventors: Mirko BIBL, Brit MOLLENHAUER, Jens WILTFANG, Hermann ESSELMANN, Piotr LEWCZUK, Johannes KORNHUBER